Alzheimer’s Drug Failure Gets a Second Life: Failed Simufilam Scaffold Reborn as PTP1B Inhibitor

In a striking example of scientific recycling, researchers have taken a drug candidate that stumbled in Phase III Alzheimer’s trials and rebuilt it from the ground up—this time aiming it at an entirely different molecular target. A team led by Vishnu Malakar and Antony Justin at JSS College of Pharmacy in Ooty, India, used network pharmacology and an arsenal of computational tools to identify protein tyrosine phosphatase 1B (PTP1B) as a promising therapeutic target for Alzheimer’s disease, then rationally redesigned 52 derivatives of simufilam, the spirocyclic drug once developed by Cassava Sciences, to inhibit it. Their lead compound, designated A20, achieved a predicted binding energy of −10.8 kcal/mol at a non-competitive allosteric site of PTP1B and maintained structural stability across molecular dynamics simulations lasting a full 1000 nanoseconds. The work, published in the journal 3 Biotech, positions A20 as a computationally validated lead candidate awaiting empirical confirmation.

The choice of PTP1B as the target is grounded in a growing body of evidence linking this enzyme to the neuroinflammatory cascade that drives Alzheimer’s pathology. PTP1B, also known as PTPN1, is best understood as a negative regulator of insulin and leptin signaling—it dephosphorylates insulin receptor substrates and dampens the JAK2 pathway. In the brain, however, its role extends into far more dangerous territory. In activated microglia, the brain’s resident immune cells, elevated PTP1B expression stimulates Src kinase activation by dephosphorylating its inhibitory tyrosine residue, which potentiates NF-κB signaling and amplifies the release of pro-inflammatory mediators including TNF-α, IL-1β, IL-6, iNOS, and COX-2. Pharmacological inhibition of PTP1B has been shown to diminish microglial activation and neuroinflammatory responses in both cell-based studies and animal models, suggesting that the enzyme actively contributes to disease progression through inflammatory mechanisms.

What makes PTP1B particularly attractive as a multi-target strategy is that it sits at the intersection of several intertwined pathological processes. Beyond its role in neuroinflammation, PTP1B directly regulates leptin receptors in hippocampal neurons and dephosphorylates tropomyosin receptor kinase B (TrkB), thereby downregulating brain-derived neurotrophic factor (BDNF) signaling—a pathway critical for synaptic plasticity and neuronal survival. It also acts as a negative regulator of IRS-1 and receptor tyrosine kinase signaling, contributing to the insulin resistance that is increasingly recognized as a risk factor for Alzheimer’s disease. Systemic metabolic conditions such as obesity and type-2 diabetes, both well-established risk factors for dementia, are linked with chronic neuroinflammation, mitochondrial impairment, and insulin resistance—all parameters that PTP1B inhibition could theoretically normalize. By contrast, the researchers argue, single-pathway approaches like BACE1 inhibitors, which failed in clinical trials due to psychiatric effects and hepatic toxicity, or GSK-3β inhibition, which carries a narrow therapeutic window, have struggled to translate into clinical success.

The simufilam scaffold itself carries an unusual history. Originally developed to restore the native conformation of filamin A, a protein that becomes abnormally connected to α7 nicotinic acetylcholine receptors in Alzheimer’s disease, simufilam progressed through Phase I and Phase II trials with favorable safety and pharmacokinetic profiles, demonstrating restoration of CSF and blood biomarkers. But its Phase III evaluation was ultimately discontinued due to insufficient efficacy. The researchers are careful to note that this failure does not necessarily invalidate the underlying scaffold—the lack of clinical benefit may reflect bioavailability limitations, off-target effects, or trial-related challenges rather than a fundamental flaw in the molecule. Given simufilam’s demonstrated brain penetration, compact spirocyclic geometry, and chemically tractable 1,3,8-triazaspiro[4.5]decan-4-one core, the team hypothesized that rational structural modification could redirect its neuroprotective activity toward PTP1B allosteric inhibition.

The design strategy was methodical. The team generated 52 simufilam derivatives by introducing diverse substituents at two positions—the R1 site on the piperidine nitrogen and the R2 site on the imidazolidinone core—while preserving the parent scaffold. The R1 modifications were engineered to reduce amine basicity, tune lipophilicity to maintain log D between 2.0 and 3.5, and sterically protect the nitrogen against cytochrome P450-mediated N-dealkylation, addressing the well-known problem that highly basic tertiary amines restrict passive blood-brain barrier permeability. The R2 derivatization was designed to probe an adjacent, under-utilized binding pocket, optimizing van der Waals contacts and hydrogen bonding capabilities to enhance selectivity over off-target receptors. The N-benzyl group at position 1 was maintained as a lipophilic anchor to preserve baseline π-π hydrophobic interactions within the binding pocket.

Before any docking was attempted, the researchers employed network pharmacology to confirm that PTP1B was the right target. They predicted compound targets using SwissTargetPrediction, retrieved Alzheimer’s disease-related targets from DisGeNET, GeneCards, and GeDiPNet, and constructed a protein-protein interaction network of 128 common targets using the STRING database and Cytoscape software. The resulting network contained 128 nodes and 1448 edges, with an average node degree of 22.6. When ranked by degree, betweenness, and closeness centrality, PTP1B emerged as the top-ranked target with a degree of 92, betweenness of 1969.41, and closeness of 0.40—outperforming other key nodes including SRC, BCL2, AKT1, and CASP3. Gene ontology enrichment analysis across biological process, molecular function, and cellular component categories, along with Reactome pathway mapping, further confirmed that the 128 active targets converge on receptor tyrosine kinase signaling, PI3K/Akt regulation, and mitogen-activated protein kinase pathways—all central to Alzheimer’s pathogenesis.

Molecular docking was performed against the non-competitive allosteric site of PTP1B using the crystal structure PDB ID 1T49, which captures the enzyme in complex with a known allosteric inhibitor. The docking protocol was validated by re-docking the co-crystallized ligand, yielding an RMSD of 0.8 Å from the experimental pose and reproducing all key native non-covalent interactions as confirmed by the Protein-Ligand Interaction Profiler webserver. Among the 52 derivatives, A20 and A26 emerged as the top-scoring leads with predicted binding energies of −10.8 and −9.5 kcal/mol, respectively. The significantly lower energy of A20 indicates a more stable protein-ligand complex. Critically, both compounds engaged residues across the catalytic and adjacent non-competitive allosteric sites, satisfying a multi-tiered consensus strategy designed to distinguish true active leads from non-specific binders.

The mechanistic insight underlying A20’s inhibitory activity is elegant. PTP1B catalysis requires dynamic motion of the flexible WPD loop, which must transition from an open state to a closed conformation to correctly position catalytic Asp181 relative to the active-site P-loop for substrate cleavage. A20 occupies a hydrophobic C-terminal non-competitive allosteric site approximately 20 Å from the active site, delineated by helices α3, α6, and α7. The o-chlorophenyl hydrazine tail at R1 establishes hydrophobic contacts and halogen interactions with Leu192, Ala189, Phe280, and Leu281, while the spiro-hydantoin core anchors the compound within the surrounding helical framework. Occupancy of this site prevents the C-terminal α7 helix from adopting the packed, ordered conformation required to facilitate WPD loop closure. By locking the WPD loop in its open, inactive state, A20 decouples substrate binding from enzymatic cleavage, reducing catalytic turnover. Because this allosteric site is distinct from the highly conserved, positively charged active site, targeting this region provides a structural basis for high isoform selectivity and improved cellular permeability.

Molecular dynamics simulations in GROMACS over 1000 nanoseconds confirmed the stability of the PTP1B-A20 complex, with consistent RMSD, RMSF, radius of gyration, hydrogen bond count, and solvent accessible surface area values throughout the trajectory. More than three hydrogen bonds remained stable over the full simulation, further supporting binding persistence. Principal component analysis revealed that A20 restricts conformational flexibility of the protein, yielding a more compact ensemble compared to the unbound state, which traverses a broader conformational landscape. MM-PBSA calculations over 1000 snapshots from the MD trajectory displayed stable binding free energies for A20, with favorable van der Waals and electrostatic contributions. Density functional theory calculations at the B3LYP/6-311+G level characterized A20’s electronic properties, revealing a dipole moment of 4.39 Debye—more polar than A26 at 3.74 Debye but less polar than the co-crystal reference at 11.54 Debye. Frontier molecular orbital analysis showed HOMO-LUMO gaps of approximately 5.4 to 5.9 eV across the key interacting residues Tyr46, Asp193, and Glu276, consistent with the electronic reactivity patterns observed in docking.

Natural bond orbital analysis further revealed that A20 is pre-organized into a compact, hydrogen bond-stabilized orientation through intramolecular O/N···H contacts at distances of 1.732 to 1.772 Å, with dominant donor-acceptor interactions involving n(O/N) to σ(N-H/C-H)* hyperconjugation and π-π* delocalization across carbonyl and aromatic fragments. These electronic features energetically favor a pre-organized conformation for site binding. ADMET profiling indicated that A20 satisfies molecular weight criteria at 370 Da, hydrogen bond donor criteria at 4 donors, and lipophilicity criteria with QPlogPo/w of 1.74, though it exhibits a single Lipinski violation from an elevated hydrogen bond acceptor count of 12.2. The researchers acknowledge that all predicted binding affinities, interaction patterns, and pharmacokinetic properties are based on theoretical models and may not fully reflect biological behavior under physiological conditions. Future development will require systematic lead optimization, including bio-isosteric modifications to improve metabolic half-life, formulation into PLGA nanoparticles to enhance aqueous solubility and CNS delivery, and in vitro PTP1B inhibition assays to confirm the computational findings. A20 is synthetically accessible through a concise two-step synthesis and targets the non-conserved α3/α6/α7 allosteric sites, providing a scaffold to guide selectivity over the homologous TCPTP enzyme in future experimental studies.

Subject of Research: Computational drug redesign of simufilam derivatives targeting PTP1B for Alzheimer's disease neuroprotection

Article Title: Network pharmacology–driven identification of PTP1β and rational design of simufilam-based allosteric inhibitors for neuroprotection in Alzheimer’s disease

Article References: Malakar, V., Raman, R., Justin, A., SP, D., Roy, D., Malakar, C. C., Purohit, D., & Mali, P. C. (2026). Network pharmacology–driven identification of PTP1β and rational design of simufilam-based allosteric inhibitors for neuroprotection in Alzheimer’s disease. 3 Biotech, 16(11), Article 467. https://doi.org/10.1007/s13205-026-05086-2

Image Credits: AI Generated

DOI: 10.1007/s13205-026-05086-2

Keywords: Alzheimer's disease, PTP1B inhibition, simufilam derivatives, network pharmacology, molecular docking, molecular dynamics simulation, MM-PBSA, density functional theory, allosteric inhibitors, neuroinflammation, drug design, computational chemistry